Cargando…
Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma
BACKGROUND: Targeted and effective treatment options are needed for solid tumors, including glioblastoma (GBM), where survival rates with standard treatments are typically less than 2 years from diagnosis. Solid tumors pose many barriers to immunotherapies, including therapy half-life and persistenc...
Autores principales: | Gardell, Jennifer L, Matsumoto, Lisa R, Chinn, Harrison, DeGolier, Kole R, Kreuser, Shannon A, Prieskorn, Brooke, Balcaitis, Stephanie, Davis, Amira, Ellenbogen, Richard G, Crane, Courtney A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597484/ https://www.ncbi.nlm.nih.gov/pubmed/33122397 http://dx.doi.org/10.1136/jitc-2020-001202 |
Ejemplares similares
-
Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
por: Brempelis, Katherine J, et al.
Publicado: (2020) -
Hypoxia-inducible lentiviral gene expression in engineered human macrophages
por: Chinn, Harrison K, et al.
Publicado: (2022) -
Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
por: Huckaby, Justin T, et al.
Publicado: (2021) -
Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Lin, Tsung-Yi, et al.
Publicado: (2021) -
Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies
por: Park, Jeong A, et al.
Publicado: (2022)